President Obama introduced his initiative to speed up the pace of research into viable treatments for Alzheimer's disease by pledging a total of $156 million in funding over the next two years. The bulk of the money, $130 million, will go to research for drugs to prevent and treat the disease, while another $26 million will be earmarked for caregiver support and public education about the disorder.
Part of the National Alzheimer's Project Act passed in January of last year, the initiative notes the heavy toll that the disease is taking on an aging U.S. population -- over 5 million Americans are estimated to have the disease, and experts fear that number could triple by 2050. Medical costs associated with Alzheimer's patients' care looms large, with experts calculating these at about $183 billion last year; totals could reach $1 trillion by 2050.
Since Obama envisions this project as a public-private partnership, some lucky pharmaceutical companies stand to benefit from this new initiative. Reasonably, companies with Alzheimer's drugs already in the pipeline or ready for testing stand to reap the greatest rewards. The only problem is that it's a been-there, done-that scenario with Alzheimer's drug research, with much effort and money producing only a handful of mediocre treatments. Unfortunately, spectacular fails seem to be the norm in this arena.
Many misses, no real hits
Time and again, promising research turned into a collection of almost-useless data as drugs that incited hope in the battle against Alzheimer's stumbled in clinical trials. Two of the most disappointing were Eli Lilly's
Alas, the four therapies currently on the market do little to control or postpone the disease for long. Three of the drugs, galantamine, rivastigmine, and donepezil are cholinesterase inhibitors, which help accentuate the effectiveness of waning amounts of acetylcholine in Alzheimer's patients' brains. Memantine is a glutamate regulator, since excessive amounts of this chemical can cause brain-cell death.
Meantime, two drugs currently under construction could be on the market by next year, if clinical trials currently finishing up produce the desired results. The drugs, solanezumab, a product of Eli Lilly, and bapineuzumab, made by Pfizer in partnership with Johnson & Johnson and Elan
This Fool's Take
Although any successful Alzheimer's treatment will raise its parent company's fortunes, the biggest winners here would be Eli Lilly, who owns solanezumab in its entirely, then Pfizer, who owns half of bapineuzumab. Coming in third would be Johnson & Johnson and Elan, each of whom have a one-quarter stake in bapineuzumab, but Elan is a much smaller company so that 25% stake could actually move the biotech's shares the most. None of these drugs promise to cure Alzheimer's, but the hope is that they will be capable of postponing symptoms of moderately-affected individuals for longer than current treatments. But that's a whole lot of patients that could conceivably be helped by these treatments. If all goes well, these companies may well have the next group of blockbuster drugs on their hands.
The healthcare field offers many opportunities for investment, but how do you know which companies to consider? Luckily, our free report, "Discover the Next Rule-Breaking Multibagger," can introduce you to some gems you may not find on your own, so sign up now!